Creative Biostructure

Online Inquiry

Please enter "biostructure" as the verification code.

Mempro™ Liposome in Cancer Therapy

Creative Biostructure has established an advanced and comprehensive Mempro™ Liposome platform to help you apply liposomes in a wide range of industrial and research fields.

Figure 1. Scheme of the of biotinylated liposomes induced by the tetrameric streptavidin protein. (D. Lombardo, et al., 2016)Figure 1. Scheme of the of biotinylated liposomes induced by the tetrameric streptavidin protein. (D. Lombardo, et al., 2016)

Mempro™ Liposome Technology has gone through intense research and development in order to improve drug delivery. Both hydrophobic and hydrophilic active molecules can be incorporated into liposomes thanks to their unique structures. Hydrophobic molecules are able to locate within the bilayer whereas hydrophilic molecules are able to located in the core of the vesicle. Liposomes are biocompatible and non-toxcity, giving rise to act as drug delivery vehicles to enhance the pharmacokinetics and bioavailability. The active encapsulated materials in the core can be small molecule drugs, antibiotics, nucleic acids, peptides and proteins. Liposomes have the unique ability to shield the inside contents from degradation in cells and to protect healthy cells from toxic drugs, making them an attractive asset in cancer therapy.

Mempro™ Liposome Technology has been applied as drug delivery vehicles in various fields, especially in cancer therapy. To successfully deliver the anti-cancer drugs, the drugs must be entrapped in the liposomes in the blood stream, moreover, the durgs are only released at the target sites. Liposomes have the distinct advantages such as non-toxicity, biocompatible, and completely biodegradable due to their natural lipids composition. Liposomes have a special advantage to incorporate both the hydrophilic and lipophilic drugs into their compartments, leading to a controlled release effect. Thanks to the minimized uptake in some tissues such as heart, gut and kidneys, the encapsulated drugs in the liposomes have shown reduced toxicity as well. The encapsulated drugs can be protected from degradation by the liposome carriers in the blood stream, furthermore, these encapsulated drugs in liposomes can be accumulated in the tumor targets by passive targeting due to the EPR (enhanced permeability and retention) effect. It is the variation between the vasculature in healthy tissues and tumor tissues which cause the EPR effect. As a result of the angiogenesis, the blood vessels have less perfect cellular packing and are more leaky in tumors, which leads to bigger gaps between the cells. Compared to normal tissues, the lymphatic system, which is able to remove the substances including liposomes and other nanoparticles from the tissues, is less expressed. Some small liposomes are able to escape vasculature within tumors and accumulate there via passive targeting effect.

Creative Biostructure is expertized in the field of liposome development, and we are more than happy to provide you the best products and outstanding services based on Mempro™ Liposome platform. Please feel free to contact us for a detailed quote.

L. Sercombe, et al. (2015). Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology, 6: A286.
A. Akbarzadeh, et al. (2013). Liposome: classification, preparation, and applications. Nanoscale Research Letters, 8: 102.
D. Lombardo, et al. (2016). Soft Interaction in Liposome Nanocarriers for Therapeutic Drug Delivery. Nanomaterials, 6: 125.

Related Sections